Total Payments
$45,228
2024 Payments
$1,590
Companies
4
Transactions
53
Medicare Patients
526
Medicare Billing
$153,879
Payment Breakdown by Category
Consulting$21,468 (47.5%)
Travel$17,563 (38.8%)
Research$4,385 (9.7%)
Food & Beverage$1,812 (4.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $21,468 | 29 | 47.5% |
| Travel and Lodging | $17,563 | 12 | 38.8% |
| Unspecified | $4,385 | 6 | 9.7% |
| Food and Beverage | $1,812 | 6 | 4.0% |
Payments by Type
General
$40,843
47 transactions
Research
$4,385
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Roche Products Limited | $15,958 | 10 | $0 (2020) |
| Genentech, Inc. | $12,150 | 17 | $0 (2020) |
| F. Hoffmann-La Roche AG | $8,887 | 10 | $0 (2024) |
| Hoffmann-La Roche Limited | $8,233 | 16 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,590 | 1 | F. Hoffmann-La Roche AG ($1,590) |
| 2022 | $465.10 | 1 | F. Hoffmann-La Roche AG ($465.10) |
| 2020 | $7,918 | 12 | F. Hoffmann-La Roche AG ($3,920) |
| 2019 | $32,061 | 33 | Roche Products Limited ($12,743) |
| 2018 | $3,194 | 6 | Roche Products Limited ($2,177) |
All Payment Transactions
53 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/08/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,590.00 | General |
| 03/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $465.10 | Research |
| Study: A PHASE II MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, 24-WEEK, 3-ARM, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO5285119 IN CHILDREN AND ADOLESCENTS AGE 5-17 WITH AUTISM SPECTRUM DISORDER ASD, A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, AND SAFETY STUDY OF BALOVAPTAN IN ADULTS WITH AUTISM SPECTRUM DISORDER WITH A 2-YEAR OPEN-LABEL EXTENSION | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $1,541.61 | Research |
| Study: V1a 2 IN PEDIATRIC AUTISM • Category: None | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $1,130.21 | Research |
| Study: V1a 2 IN PEDIATRIC AUTISM and Phase III study of Balovaptan in Adults with ASD • Category: None | ||||||
| 11/18/2020 | Roche Products Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $1,037.50 | General |
| Category: None | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $595.56 | Research |
| Study: A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder ASD • Category: None | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $410.32 | Research |
| Study: A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder ASD, A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, AND SAFETY STUDY OF Balovaptan IN adults WITH AUTISM SPECTRUM DISORDER with a 2-year open-label extension • Category: None | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $242.39 | Research |
| Study: A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder ASD, A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, AND SAFETY STUDY OF Balovaptan IN adults WITH AUTISM SPECTRUM DISORDER with a 2-year open-label extension • Category: None | ||||||
| 03/06/2020 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $185.00 | General |
| 02/26/2020 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 02/26/2020 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $185.00 | General |
| Category: None | ||||||
| 01/28/2020 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $370.00 | General |
| Category: None | ||||||
| 01/21/2020 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $740.00 | General |
| Category: None | ||||||
| 01/07/2020 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $370.00 | General |
| 12/11/2019 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $370.00 | General |
| Category: None | ||||||
| 12/07/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $1,510.97 | General |
| Category: None | ||||||
| 12/07/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $999.00 | General |
| Category: None | ||||||
| 12/07/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $402.07 | General |
| Category: None | ||||||
| 10/24/2019 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $185.00 | General |
| 09/13/2019 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $185.00 | General |
| 09/11/2019 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $185.00 | General |
| Category: None | ||||||
| 08/02/2019 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $185.00 | General |
| Category: None | ||||||
| 07/22/2019 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $185.00 | General |
| Category: None | ||||||
| 07/17/2019 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $370.00 | General |
| Category: None | ||||||
| 07/15/2019 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $370.00 | General |
| Category: None | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| V1a 2 IN PEDIATRIC AUTISM | F. Hoffmann-La Roche AG | $1,542 | 1 |
| V1a 2 IN PEDIATRIC AUTISM and Phase III study of Balovaptan in Adults with ASD | F. Hoffmann-La Roche AG | $1,130 | 1 |
| A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder ASD, A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, AND SAFETY STUDY OF Balovaptan IN adults WITH AUTISM SPECTRUM DISORDER with a 2-year open-label extension | F. Hoffmann-La Roche AG | $652.71 | 2 |
| A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder ASD | F. Hoffmann-La Roche AG | $595.56 | 1 |
| A PHASE II MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, 24-WEEK, 3-ARM, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO5285119 IN CHILDREN AND ADOLESCENTS AGE 5-17 WITH AUTISM SPECTRUM DISORDER ASD, A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, AND SAFETY STUDY OF BALOVAPTAN IN ADULTS WITH AUTISM SPECTRUM DISORDER WITH A 2-YEAR OPEN-LABEL EXTENSION | F. Hoffmann-La Roche AG | $465.10 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 102 | 357 | $139,164 | $36,504 |
| 2022 | 2 | 127 | 380 | $87,860 | $37,804 |
| 2021 | 2 | 129 | 403 | $95,073 | $42,786 |
| 2020 | 4 | 168 | 396 | $95,344 | $36,785 |
Total Patients
526
Total Services
1,536
Medicare Billing
$153,879
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 86 | 332 | $134,034 | $34,934 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 25 | $5,130 | $1,570 | 30.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 286 | $71,786 | $30,546 | 42.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 45 | 94 | $16,074 | $7,258 | 45.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 86 | 327 | $82,077 | $36,835 | 44.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 43 | 76 | $12,996 | $5,951 | 45.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 93 | 295 | $74,045 | $28,361 | 38.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 30 | 44 | $7,524 | $2,907 | 38.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 25 | 32 | $5,300 | $2,873 | 54.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 20 | 25 | $8,475 | $2,644 | 31.2% |
About Dr. Russell Tobe, MD
Dr. Russell Tobe, MD is a Psychiatry healthcare provider based in Orangeburg, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2008. The National Provider Identifier (NPI) number assigned to this provider is 1659539773.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Russell Tobe, MD has received a total of $45,228 in payments from pharmaceutical and medical device companies, with $1,590 received in 2024. These payments were reported across 53 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($21,468).
As a Medicare-enrolled provider, Tobe has provided services to 526 Medicare beneficiaries, totaling 1,536 services with total Medicare billing of $153,879. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Child & Adolescent Psychiatry, Child & Adolescent Psychiatry
- Location Orangeburg, NY
- Active Since 05/27/2008
- Last Updated 11/18/2025
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659539773
Products in Payments
- Non-Covered Product (Drug) $35,865
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Orangeburg
Dr. Joshua Kantrowitz, M.d, M.D
Psychiatry — Payments: $20,180
Psychiatry $20,180
Ralph Nixon, M.d, M.D
Psychiatry — Payments: $4,985
Psychiatry $4,985
Mr. Alberto Gonzalez, Md, MD
Psychiatry — Payments: $3,711
Psychiatry $3,711
Dr. Lina Haber, M.d, M.D
Psychiatry — Payments: $3,660
Psychiatry $3,660
Anthony Sciarrone, Md, MD
Psychiatry — Payments: $3,195
Psychiatry $3,195
Noshin Chowdhury, M.d, M.D
Psychiatry — Payments: $2,605
Psychiatry $2,605